首页> 美国卫生研究院文献>Current Neuropharmacology >Can We Selectively Reduce Appetite for Energy-Dense Foods? An Overview of Pharmacological Strategies for Modification of Food Preference Behavior
【2h】

Can We Selectively Reduce Appetite for Energy-Dense Foods? An Overview of Pharmacological Strategies for Modification of Food Preference Behavior

机译:我们可以选择性地降低对高能量食品的食欲吗?改变食物偏爱行为的药理策略概述

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Excessive intake of food, especially palatable and energy-dense carbohydrates and fats, is largely responsible for the growing incidence of obesity worldwide. Although there are a number of candidate antiobesity drugs, only a few of them have been proven able to inhibit appetite for palatable foods without the concurrent reduction in regular food consumption. In this review, we discuss the interrelationships between homeostatic and hedonic food intake control mechanisms in promoting overeating with palatable foods and assess the potential usefulness of systemically administered pharmaceuticals that impinge on the endogenous cannabinoid, opioid, aminergic, cholinergic, and peptidergic systems in the modification of food preference behavior. Also, certain dietary supplements with the potency to reduce specifically palatable food intake are presented. Based on human and animal studies, we indicate the most promising therapies and agents that influence the effectiveness of appetite-modifying drugs. It should be stressed, however, that most of the data included in our review come from preclinical studies; therefore, further investigations aimed at confirming the effectiveness and safety of the aforementioned medications in the treatment of obese humans are necessary.
机译:过量摄入食物,尤其是可口且能量密集的碳水化合物和脂肪,是导致肥胖症发病率上升的主要原因。尽管有许多候选的减肥药,但只有少数几种被证明能够抑制可口食品的食欲而不会同时减少常规食品的消费。在这篇综述中,我们讨论了稳态和享乐性食物摄入控制机制之间的相互关系,以促进可口食物的暴饮暴食,并评估全身给药的药物对修饰中内源性大麻素,阿片样物质,胺能,胆碱能和肽能系统的潜在作用食物偏爱行为。此外,还提出了某些具有减少特定可口食物摄入量的功效的膳食补充剂。根据人类和动物研究,我们指出了影响食欲改变药物功效的最有前途的疗法和药物。应该强调的是,我们的评价中包括的大多数数据来自临床前研究。因此,有必要进行进一步的研究以证实上述药物在肥胖人的治疗中的有效性和安全性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号